• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ALX
Click for more information
0.00% $4.79

ATLAS ARTERIA - Charts / Financials

Market Cap $6.949B  ! watchlist Created with Sketch. Add to my watchlist
Industrials Railroads

Atlas Arteria Group is an Australia-based global owner, operator, and developer of toll... Atlas Arteria Group is an Australia-based global owner, operator, and developer of toll roads. The Company has a portfolio of five toll roads in France, Germany, and the United States. The Company owns a 31.14% interest in the Autoroutes Paris-Rhin-Rhone (APRR) toll road group in France. In addition to the APRR business is the smaller Autoroute des deux lacs (ADELAC) business, which connects to APRR in southeast France. Together APRR and ADELAC comprise approximately 2,424 kilometers of motorway network located in the East and Southeast of France. In the United States, it owns a 66.67% interest in the Chicago Skyway, a 12.5 kilometers toll road in Chicago and has 100% of the economic interest in the Dulles Greenway, a 22 kilometers toll road in the Commonwealth of Virginia. In Germany, it owns 100% of the Warnow Tunnel in the northeast city of Rostock.More

refresh Created with Sketch. REFRESH
Last update - 10.59am 02/10/2024 (20 minute delay) ?
Day
Open $4.81   Day High $4.86   Day Low $4.77
Daily Volume 130264
Bids   Sellers
Number Price Volume   Number Price Volume
12 $4.78 4064   20 $4.79 18815

Directors & Senior Management

Mr. Graeme Bevans Chief Executive Officer, Managing Director, Executive Director
Mr. David Collins Chief Financial Officer
Mr. Vincent Portal-Barrault Chief Operating Officer
Mr. Clayton McCormack General Counsel, Joint Company Secretary
Ms. Amanda Baxter Group Executive North America and Corporate Development
Ms. Catherine Brain Group Executive, People and Culture
Mr. Paul Lynch Joint Company Secretary
Ms. Debra L Goodin Non-Executive Independent Chairman of the Board of ATLAX, Independent Non- Executive Director of ATLIX
Mr. Ken Daley Non-Executive Director
Mr. Danny Elia Non-Executive Director of ATLAX
Mr. David Bartholomew Non-Executive Independent Director of ATLAX
Ms. Fiona E. Beck Non-Executive Independent Director of ATLIX

Data source: Refinitiv

(20min delay)
Last
$4.79 		Change
0.000(0.00%) 		Mkt cap ! $6.949B
Open High Low Value Volume
$4.81 $4.86 $4.77 $625.5K 130.2K

Buyers (Bids)

No. Vol. Price($)
12 4064 $4.78
 

Sellers (Offers)

Price($) Vol. No.
$4.79 18815 20
View Market Depth
Last trade - 10.39am 02/10/2024 (20 minute delay) ?
Last
$4.79 		  Change
0.000 ( 0.11 %)
Open High Low Volume
$4.84 $4.84 $4.77 33190
Last updated 10.59am 02/10/2024 ?

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Firebird achieves preliminary approvals for its Jinshi plant design Firebird Metals Ltd has reached a significant stage in development of its battery-grade manganese sulphate plant in China
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.